false
Catalog
2021 Webinar: To Stop or Not to Stop: The Practice ...
To Stop or Not to Stop: The Practice of Finite Nuc ...
To Stop or Not to Stop: The Practice of Finite Nucleos(t)ide Analog Therapy
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this ASLD webinar, experts discussed the practice of finite nucleoside nucleotide analog therapy in patients with chronic hepatitis B. The lack of effective nucleoside analogs on covalently closed circular DNA and integrated HPV DNA means that chronic hepatitis B cannot be cured. Treatment guidelines recommend only discontinuing nucleoside analog therapy once surface antigen loss is achieved. However, interest in stopping antiviral therapy was rekindled after a study reported a high rate of surface antigen loss, 39%, after stopping continuous therapy. The experts presented evidence supporting both finite therapy and continued therapy. Dr. Jiang argued for finite therapy, citing patient willingness, adherence, and cost concerns. She also highlighted that hepatitis B surface antigen decline is slow during treatment, and the medication cost for lifelong treatment is a concern. Dr. Janssen argued against stopping therapy, noting the significant benefits of antiviral therapy in improving liver fibrosis, reversing cirrhosis, reducing liver cancer risk, and decreasing liver-related mortality. He also mentioned the risk of ALT flares and the potential for dangerous flares and decompensation after stopping therapy. The experts discussed the timing of retreatment after clinical relapse, with Dr. Jiang emphasizing the importance of strict monitoring and a patient's ALT level. Dr. Janssen highlighted the need for standardized retreatment criteria and the challenge of balancing safety and achieving surface antigen loss. They both agreed that long-term follow-up and more data are needed to make definitive recommendations.
Asset Caption
Presenters: Wen-Juei Jeng, MD and Harry Janssen, MD, PhD, FAASLD
Moderators: Marc Ghany, MD, FAASLD and Yao-Chun Hsu, MD, MSc, PhD
Keywords
ASLD webinar
finite nucleoside nucleotide analog therapy
chronic hepatitis B
nucleoside analogs
covalently closed circular DNA
integrated HPV DNA
surface antigen loss
antiviral therapy
liver fibrosis
cirrhosis
liver cancer risk
×
Please select your language
1
English